[go: up one dir, main page]

AR011706A1 - Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis - Google Patents

Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis

Info

Publication number
AR011706A1
AR011706A1 ARP980101499A ARP980101499A AR011706A1 AR 011706 A1 AR011706 A1 AR 011706A1 AR P980101499 A ARP980101499 A AR P980101499A AR P980101499 A ARP980101499 A AR P980101499A AR 011706 A1 AR011706 A1 AR 011706A1
Authority
AR
Argentina
Prior art keywords
tuberculosis
prevention
treatment
containment
tobramycin
Prior art date
Application number
ARP980101499A
Other languages
English (en)
Original Assignee
Pathogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogenesis Corp filed Critical Pathogenesis Corp
Publication of AR011706A1 publication Critical patent/AR011706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El tratamiento y prevencion de la tuberculosis pulmonar por vía sistémica ya no es recomendable por el hecho que las concentraciones necesarias en sangreson muy proximas a aquéllas que pueden provocar acciones toxicas. Ello se ha traducido a quehoy se recurra a formulaciones, fundamentalmente a base deantibioticos, de accion local. No obstante, dado que las secreciones bronquiales son de difícil penetracion, aparte de actuar como inhibidoras de laactividad propia de aquellas drogas, los resultados no han sido los esperados. Mediante esta invencion se provee una formulacion a base de una altaconcentracion, comprendida entre 1.000 y 10.000 veces la concentracion inhibitoria mínima de la bacteria Mycobactrium tuberculosis, de tobramicina,en un pequeno volumen de solucion salina con un pH comprendido entre 5,0 y 7,5 que, aplicada, en aerosol en partículas cuyo tamano oscila entre 1 y 5 micronesaproximadamente, resulta altamente eficaz para la inhibicion y destruccion de tal bacteria.
ARP980101499A 1997-04-02 1998-04-02 Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis AR011706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/825,725 US6083922A (en) 1996-04-02 1997-04-02 Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Publications (1)

Publication Number Publication Date
AR011706A1 true AR011706A1 (es) 2000-08-30

Family

ID=25244769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101499A AR011706A1 (es) 1997-04-02 1998-04-02 Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis

Country Status (7)

Country Link
US (1) US6083922A (es)
AR (1) AR011706A1 (es)
AU (1) AU6469198A (es)
BR (1) BR9801008A (es)
IL (1) IL123848A (es)
WO (1) WO1998043650A1 (es)
ZA (1) ZA982447B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2002247280A1 (en) * 2001-03-09 2002-09-24 Antares Pharma, Inc. Ocular drug delivery nebulizer
AU2007202942B2 (en) * 2001-05-18 2010-05-27 Novartis Ag Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
PT1320355E (pt) * 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
CA2526362C (en) 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
RU2243776C1 (ru) * 2003-07-08 2005-01-10 Новосибирский научно-исследовательский институт туберкулёза (ННИИТ) Способ лечения туберкулеза легких
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
ATE493969T1 (de) * 2004-05-17 2011-01-15 Corus Pharma Inc Kombination aus fosfomycin/aminoglycosid in aerosolform zur behandlung bakterieller atemwegsinfektionen
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
JP2008539890A (ja) * 2005-05-05 2008-11-20 プルマトリックス インコーポレイテッド 超音波式エアロゾルゼネレーター
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006247077A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
DK1901749T3 (en) 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US9205050B2 (en) 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
EP2049139A4 (en) 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
ES2639065T5 (es) 2009-06-25 2023-01-30 Alkermes Pharma Ireland Ltd Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
US20110014273A1 (en) * 2009-07-15 2011-01-20 Helmut Brunar Method of Treating BCC
EP3569235A1 (en) 2009-09-04 2019-11-20 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2805425C (en) 2010-07-15 2019-07-23 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
EP2593056B1 (en) 2010-07-15 2020-10-21 Eyenovia, Inc. Drop generating device
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
AU2011348085B2 (en) 2010-12-23 2016-12-08 Alkermes Pharma Ireland Limited Multi- API loading prodrugs
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
PE20141382A1 (es) 2011-04-01 2014-11-04 Curis Inc Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc
US20130150812A1 (en) 2011-12-12 2013-06-13 Corinthian Ophthalmic, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
EP2790703B1 (en) 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
JP6501264B2 (ja) 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2017516463A (ja) 2014-03-31 2017-06-22 デバイオファーム インターナショナル エスエイ Ｆｇｆｒ融合体
CA2959104A1 (en) 2014-08-26 2016-03-03 Hsf Pharmaceuticals Novel immunization agents and methods of use
AU2015328307B2 (en) 2014-10-06 2019-11-21 Apm Therapeutics 1, Inc. Triazolopyridine compounds and methods for the treatment of cystic fibrosis
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
US11597708B2 (en) 2016-09-16 2023-03-07 Hsf Pharmaceuticals Sa Inhibitors of heat shock factors and uses thereof
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
NZ762994A (en) 2017-08-28 2025-11-28 Enanta Pharm Inc Hepatitis b antiviral agents
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
US20210401968A1 (en) 2018-03-08 2021-12-30 Hsf Pharmaceuticals Sa Localized activation of virus replicatio boosts herpesvirus-vectored vaccines
CN112088016A (zh) 2018-05-10 2020-12-15 化工研究所有限公司 含有多种活性剂分子的生物相容性共聚物
EP3840737A1 (en) 2018-08-23 2021-06-30 MannKind Corporation Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3112177A1 (en) 2018-09-11 2020-03-19 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AR116474A1 (es) 2018-09-21 2021-05-12 Enanta Pharm Inc DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
EP3653716A1 (en) 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
GB2599818B (en) 2019-06-04 2024-01-31 Thirty Respiratory Ltd Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
BR112021023832A8 (pt) 2019-06-04 2023-02-28 Thirty Holdings Ltd Métodos e composições para geração de óxido nítrico e usos dos mesmos
KR20220092565A (ko) 2019-10-30 2022-07-01 씨아이에스 파르마 에이쥐 활성제를 전달하기 위한 생체 적합성 중합체 약물 담체
EP4069216A4 (en) 2019-12-05 2023-12-27 Flatley Discovery Lab, LLC COMPOUNDS AND METHODS FOR TREATING CYSTIC FIBROSIS
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
US20240016831A1 (en) 2020-04-23 2024-01-18 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
EP4138794A1 (en) 2020-04-23 2023-03-01 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
EP4138898A1 (en) 2020-04-24 2023-03-01 HSF Pharmaceuticals Replication-competent controlled herpesviruses expressing a sars cov-2 antigen
JP2023528404A (ja) 2020-06-01 2023-07-04 アドベント セラピューティクス インコーポレイテッド 不溶性活性成分を含む医薬組成物
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
GB2607514B (en) 2020-07-20 2023-06-21 Enanta Pharm Inc Functionalized peptides as antiviral agents
CA3173333A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof
WO2025214935A1 (en) 2024-04-11 2025-10-16 Hsf Pharmaceuticals Sa Recombinant alphaherpesvirus vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization

Also Published As

Publication number Publication date
IL123848A0 (en) 1998-10-30
AU6469198A (en) 1998-10-22
WO1998043650A1 (en) 1998-10-08
US6083922A (en) 2000-07-04
ZA982447B (en) 1999-01-26
BR9801008A (pt) 2001-03-20
IL123848A (en) 2002-12-01

Similar Documents

Publication Publication Date Title
AR011706A1 (es) Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis
CO4940408A1 (es) Composicion de aerosol farmaceutico
DK0918507T3 (da) Aerosolformuleringer
BR9907057A (pt) Composição perfumante antimicrobiana, artigo perfumado e utilização da composição.
GT199900197A (es) Formulaciones antiparasitarias.
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AR019772A1 (es) Composiciones antimicrobianas en aerosol
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
DE59909615D1 (de) Mittel zur abwehr und inaktivierung pathogener erreger von pflanzen
DE69501419D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
FI813857L (fi) Abrasivt verkande medel och deras anvaendning
AR038333A1 (es) Desinfectante/esterilizante de baja temperatura para dipositivos medicos y aplicaciones topicas
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
ES2177324T3 (es) Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
PT1251737E (pt) Composicoes tratadas para inactivar proteinas infecciosas
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
ES2130102T1 (es) Composicion cosmetica adelgazante que contiene un extracto de chrysanthellum indicum.
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
DE69011130D1 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.

Legal Events

Date Code Title Description
FC Refusal